Published August 24, 2026
Every morning our data team scans the GLP-1 wire for stories that will actually matter to people who eat on these medications. This one — 'Wegovy for teens: fewer than 1 in 100 adolescents with…', from a news source on 2026-09-02 — made the cut, and the analysis below connects it to the food data rather than repeating the press release.
This story is on our radar. We cover GLP-1 news by checking the source, then reading it through the same food lens we use everywhere: protein, fiber and fat. Where a story makes food claims, the USDA data is the referee.
The pattern behind almost every GLP-1 food question is the same three variables, and it is worth restating because headlines keep circling back to it: protein protects muscle during weight loss, fat predicts nausea on a slowed stomach, and fiber plus water manages constipation. Exactly those three measures are what this site scores on.
Whatever the angle of the story — heart, kidney, muscle, side effects — the practical food response is remarkably consistent. That consistency is deliberate: the verdict labels are a fixed reference, so a reader does not need the news to know what to eat on any given day.
The honest limit: clinical stories are for clinicians. Food data answers 'what is in the food'; whether a headline applies to your dose, your body, or your treatment is a question for your healthcare provider. This post stays on the food side of that line, and says so out loud.
Our coverage filter is simple and it applies to every story: recent, traceable to a named source, and relevant to the food side of GLP-1 life. Anything that cannot be linked does not get a page — the same rule the site applies to its food data.
What this story changes on your plate: traceable sources and food data.
Protein first, vegetables second, small servings of the heavy stuff — the same structure as every other day, whatever the news.
Fat is the nausea lever and fiber-plus-water is the regularity lever; those two rules cover most of what side-effect headlines describe.
And the standing rule: news informs, it does not prescribe — your dose and symptom questions are for your clinician.
Seven days balance each other out — the celebration and the quiet meal both count. The week view is the honest scoreboard for a GLP-1 routine. The week is the honest sample: big enough to mean something, small enough to manage.
One frame covers most meals: protein first, produce filling, a modest quarter for the heavier item. It is repeatable, which is what makes it work on a GLP-1. That shape also makes it easy to adjust: smaller when the stomach is slow, fuller on a good day.
Boring is the goal; the repetition of the same shape is what produces the results, so no adjustment is the right adjustment. The food fixes are free to try; the clinician's judgment is not something a published record can replace.
Relevance is mostly indirect: a study changes which nutrient gets attention, not the food pattern itself. The pattern — protein first, portions small, fiber and water constant — survives every headline, and the published method stays the reference for whichever nutrient the story highlights. Your dose and treatment questions remain your clinician's job.
No story should send you to a different plate by itself. The site's verdicts are built on USDA data and published frameworks, which change slowly and deliberately, not per news cycle. If a headline genuinely applies to you — your dose, your symptoms — that is a conversation for your clinician, not a menu rewrite.
The checklist is short: is there a named source, a date, and a study or agency behind it? FDA, peer-reviewed journals and established health media clear the bar; headlines with no link and no study do not. Watch for single-trial overreach too. This post links its source openly, which is the standard we apply to ourselves.
There is no quota. The useful habit is to check when a story matters to you — a change in guidance, a new study on side effects — and to let the site's stable verdicts handle the day-to-day. News informs; your clinician manages your treatment; the plate pattern sits between them, unchanged.
Source: a news source · 2026-09-02. We cite the source openly and limit our own claims to the food data, which is the part this site can verify.
The whole site runs on the same discipline: public USDA data, a consistent screen, and named guidelines. The published records behind the links are the reference for every number this post uses.
Portions on a GLP-1 are smaller than the old portions, and that is the point: the medication slows emptying and quietens hunger, so a plate that used to feel right may now feel like twice as much. The practical move is to serve less than you think you need, eat slowly, and treat the first signal of fullness as the stop line. Protein keeps its place at the centre of the smaller plate, because the muscle you keep during weight loss matters more than the volume you eat. This page's scored entries rank by per-100g value, which is the reference for building that smaller, denser plate.
The headline first: 'Eye doctors' consensus: GLP-1s may modestly raise rare optic-nerve risk, bu
Next-gen GLP-1s outperform Mounjaro: 38-trial analysis puts…This one came across our desk from Annals of Internal Medicine network meta-analysis via AOL (Aug 2026) on 202
Semaglutide and alcohol: three human trials, three different…When a GLP-1 story lands in the news, the question our readers ask is usually the same: does this change what